Kirsten White

机构：Gilead Sciences (United States), Gilead Sciences (Australia) · ORCID：0000-0002-5576-5196

发表论文 110 篇 · 总被引 5638 次 · h-index 38

代表论文

• High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I (2022 · AIDS · 被引 41)
• Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight (2020 · PLoS ONE · 被引 40)
• Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 35)
• Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes (2021 · Antimicrobial Agents and Chemotherapy · 被引 33)
• Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants (2021 · Journal of Antimicrobial Chemotherapy · 被引 15)
• Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen (2020 · International Journal of Antimicrobial Agents · 被引 15)